Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

Apr 22, 2020

SELL
$40.01 - $73.97 $400,100 - $739,700
-10,000 Closed
0 $0
Q4 2019

Feb 03, 2020

BUY
$37.13 - $74.62 $371,300 - $746,200
10,000 New
10,000 $716,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Exane Asset Management Portfolio

Follow Exane Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Exane Asset Management with notifications on news.